Observational studyPloS one2025
Epidemiological characteristics and management of Gram-negative bacteraemia in different immunocompromised hosts: Observational single-center study.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Scenario-Based Survey of Clinician Recommendations for Follow-Up Blood Cultures in Patients With Varying Risk of Persistent Gram-Negative Bacteremia.Open forum infectious diseases · 2026Article
- Managing multidrug resistant Gram-negative bacteraemia in immunocompromised hosts.Current opinion in infectious diseases · 2026Review
- Implementation of a Bundle for the Management of Patients With Gram-Negative Bloodstream Infection: A Pre-Post Quasi-experimental Study.Open forum infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importancePatients with Gram-negative bloodstream infections (GN-BSI) are classified as non-immunocompromised (n-IC) or immunocompromised (IC). However, immunosuppressive condition should not be considered univocally.
objectiveTo investigate epidemiological characteristics, management and outcome of GN-BSI in IC and non-IC patients.
methodsRetrospective single-center study of hospitalized patients with GN-BSI conducted over a 7-year period. Patients with GN-BSI were divided in: solid organ transplant (SOT) recipients, patients with hematologic malignancy (HM), patients with metastatic solid cancer (mSC), and non-major IC patients (nm-IC).
results3544 patients analysed: 76.7% nm-IC, 6.5% SOT, 8.0% HM and 8.8% mSC. SOT and HM patients were younger (SOT: 56.6 ± 13.1 years; HM: 56.4 ± 14.5; nm-IC: 72.4 ± 16.1; mSC: 68.6 ± 13.1, p < 0.001) and had lower CCI value (SOT: 4.5 ± 2.4; HM: 4.1 ± 2.1; nm-IC: 5.5 ± 2.6; mSC: 9.7 ± 2.5, p < 0.001). Urinary tract infection was the most common source of BSI in nm-IC (nm-IC: 50.1%, HM:15%; SOT: 33.3%; mSC: 25.9%, p < 0.001), intra-abdominal infection was the more frequent source among SOT and mSC (SOT:42.3%; mSC: 49.3%, nm-IC: 27.8%, HM:29%; p < 0.001). Primary BSI was the first cause of GN-BSI in HM (HM: 62.1%; SOT: 18.5%; nm-IC: 17.2%; mSC: 10.6%, p < 0.001). The lowest rate of death was observed in SOT and the highest in mSC (SOT 8.2%; nm-IC 13.4%; HM 14.9%; mSC 19.9%, p < 0.001). Relapse rate was highest in SOT (SOT: 18.8%; HM: 11.8%; NMIC: 7.2%; aST: 7.1%, p < 0.001). Follow-up bloodcultures were associated with a lower mortality only among NMIC (HR = 0.317, 95% CI 0.178-0.563, p < 0.001) and aST (HR = 0.198, 95% CI 0.058-0.673, p = 0.010). The role of treatment duration on relapse was not evident in any group, conversely receiving at least 7 days of treatment was associated with a lower risk of 90-day mortality in SOT and HM patients.
conclusionsThe characteristics and outcome of GN-BSI are peculiar between specific IC categories, therefore a personalized management should be implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.